Passage Bio Inc
(NAS:PASG)
$
0.657
-0.0029 (-0.44%)
Market Cap: 40.58 Mil
Enterprise Value: -18.43 Mil
PE Ratio: 0
PB Ratio: 0.56
GF Score: 36/100 Passage Bio Inc at Guggenheim Genomic Medicines and Rare Disease Day (Virtual) Transcript
Mar 31, 2022 / 01:00PM GMT
Release Date Price:
$3.1
(+1.64%)
Debjit Chattopadhyay
Guggenheim Securities, LLC - Analyst
Awesome. Good morning and thank you for joining Guggenheim's Genomic Medicine and Rare Disease Conference. I am Debjit Chattopadhyay, one of the therapeutics analysts representing Guggenheim therapeutics team. And my privilege today to host Passage Bio's President and CEO, Dr. Bruce Goldsmith.
Good morning, Bruce, and thank you for your time.
Bruce Goldsmith
Passage Bio, Inc. - President & CEO
Yeah. Good morning. Thanks for having us -- or me, I should say.
Questions & Answers
Debjit Chattopadhyay
Guggenheim Securities, LLC - Analyst
Great. Well, it's been sort of a really rough year for gene therapy in general. Pandemic hasn't obviously made things easier in terms of enrollment stuff. So what are some of the key initiatives within Passage which should limit execution risk as you go forward?
Bruce Goldsmith
Passage Bio, Inc. - President & CEO
Yeah, absolutely. It's a great question
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot